Please login to the form below

Not currently logged in

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Kramer, while Biogen’s chief medical officer Alfred Sandrock said the data “underscores that neurodegenerative diseases may not be as intractable as they once seemed.”.

Latest news

More from news
Approximately 3 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... The company has a focus in neurodegenerative diseases and a technology, Antibody Transport Vehicle (ATV) technology, which can enhance blood-brain barrier

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... These deals were mainly early stage deals in the areas of

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil). ... acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and

  • Deal Watch February 2016 Deal Watch February 2016

    Pronutria's focus is on the development of therapeutics and nutritional supplements for diseases caused by amino acid imbalances. ... The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....